These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32560609)

  • 1. Xanthone: A Promising Antimycobacterial Scaffold.
    Elsaman T; Mohamed MS; Eltayib EM; Abdalla AE; Mohamed MA
    Med Chem; 2021; 17(4):310-331. PubMed ID: 32560609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.
    Koh JJ; Zou H; Mukherjee D; Lin S; Lim F; Tan JK; Tan DZ; Stocker BL; Timmer MSM; Corkran HM; Lakshminarayanan R; Tan DTH; Cao D; Beuerman RW; Dick T; Liu S
    Eur J Med Chem; 2016 Nov; 123():684-703. PubMed ID: 27517813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increment of antimycobaterial activity on lichexanthone derivatives.
    Micheletti AC; Honda NK; Pavan FR; Leite CQ; Matos Mde F; Perdomo RT; Bogo D; Alcantara GB; Beatriz A
    Med Chem; 2013 Nov; 9(7):904-10. PubMed ID: 23106287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances on Natural and Non-Natural Xanthones as Potential Anticancer Agents: A Review.
    Gogoi U; Pathak K; Saikia R; Pathak MP; Paul T; Khan SA; Das A
    Med Chem; 2023; 19(8):757-784. PubMed ID: 36573047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current development of 5-nitrofuran-2-yl derivatives as antitubercular agents.
    Elsaman T; Mohamed MS; Mohamed MA
    Bioorg Chem; 2019 Jul; 88():102969. PubMed ID: 31077910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and antimycobacterial assay of some xanthone derivatives.
    Szkaradek N; Stachura K; Waszkielewicz AM; Cegła M; Szneler E; Marona H
    Acta Pol Pharm; 2008; 65(1):21-8. PubMed ID: 18536169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent cancer drug development with xanthone structures.
    Na Y
    J Pharm Pharmacol; 2009 Jun; 61(6):707-12. PubMed ID: 19505360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review on anti-tuberculosis peptides: Impact of peptide structure on anti-tuberculosis activity.
    Yathursan S; Wiles S; Read H; Sarojini V
    J Pept Sci; 2019 Nov; 25(11):e3213. PubMed ID: 31515916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structures, Activities and Drug-Likeness of Anti-Infective Xanthone Derivatives Isolated from the Marine Environment: A Review.
    Loureiro DRP; Soares JX; Costa JC; Magalhães ÁF; Azevedo CMG; Pinto MMM; Afonso CMM
    Molecules; 2019 Jan; 24(2):. PubMed ID: 30634698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.
    Guillemont J; Meyer C; Poncelet A; Bourdrez X; Andries K
    Future Med Chem; 2011 Sep; 3(11):1345-60. PubMed ID: 21879841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities.
    Tomioka H
    Curr Pharm Des; 2006; 12(31):4047-70. PubMed ID: 17100611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
    Martins F; Ventura C; Santos S; Viveiros M
    Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent activity against multidrug-resistant Mycobacterium tuberculosis of α-mangostin analogs.
    Sudta P; Jiarawapi P; Suksamrarn A; Hongmanee P; Suksamrarn S
    Chem Pharm Bull (Tokyo); 2013; 61(2):194-203. PubMed ID: 23150066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.